Perrigo (PRGO) Income towards Parent Company (2012 - 2026)
Perrigo (PRGO) posted quarterly Income towards Parent Company of -$8.7 million for Q1 2026, down 33.85% year-over-year from -$13.2 million in Q1 2025, and down 148.57% quarter-over-quarter from -$3.5 million in Q4 2025.
Perrigo (PRGO) Income towards Parent Company (2012 - 2026) Analysis & Trends
Perrigo (PRGO) has reported Income towards Parent Company for 15 consecutive years, with -$8.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Income towards Parent Company fell 33.85% year-over-year to -$8.7 million; the TTM figure through Mar 2026 stood at -$25.3 million (down 62.18% YoY), while the FY2025 annual figure was -$23.1 million, down 108.11% from the prior year.
- Income towards Parent Company declined to -$8.7 million in Q1 2026 per PRGO's latest filing, from -$3.5 million in the prior quarter.
- Across five years, Income towards Parent Company topped out at $2.7 million in Q4 2022 and bottomed at -$11.0 million in Q4 2022.
- Historically, Income towards Parent Company has averaged -$3.6 million across 5 years, with a median of -$3.0 million in 2024.
- Annual changes were most pronounced in 2022 — Income towards Parent Company jumped 154.0% — and 2024, when it plunged 440.0%.
- Perrigo's Income towards Parent Company stood at -$11.0 million in 2022, then jumped by 58.18% to -$4.6 million in 2023, then surged by 34.78% to -$3.0 million in 2024, then fell by 16.67% to -$3.5 million in 2025, then sank by 148.57% to -$8.7 million in 2026.
- Business Quant data shows PRGO's Income towards Parent Company at -$8.7 million in Q1 2026, -$3.5 million in Q4 2025, and -$5.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.81 Bn | 42.84 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.29 Bn | 39.63 Bn | 2.15 Bn |
| 3 | Zoetis | 31.59 Bn | 29.91 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.67 Bn | 22.88 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.24 Bn | 19.58 Bn | 683.80 Mn |
| 6 | Viatris | 18.79 Bn | 17.91 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.71 Bn | 15.32 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 12.09 Bn | 11.56 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - |
| 10 | Perrigo | 1.89 Bn | 1.49 Bn | 313.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 27, 2026 | -14.10 Mn |
| Mar 28, 2026 | -8.70 Mn |
| Dec 31, 2025 | -3.50 Mn |
| Sep 27, 2025 | -5.20 Mn |
| Jun 28, 2025 | -7.90 Mn |
| Mar 29, 2025 | -6.50 Mn |
| Dec 31, 2024 | -3.00 Mn |
| Sep 28, 2024 | -3.40 Mn |
| Jun 29, 2024 | -2.70 Mn |
| Mar 30, 2024 | -2.10 Mn |
| Dec 31, 2023 | -4.60 Mn |
| Sep 30, 2023 | -1.20 Mn |
| Jul 1, 2023 | -500,000.00 |
| Apr 1, 2023 | -1.90 Mn |
| Dec 31, 2022 | -11.00 Mn |
| Oct 1, 2022 | 2.70 Mn |
| Jul 2, 2022 | -200,000.00 |
| Apr 2, 2022 | -1.10 Mn |
| Dec 31, 2021 | -22.50 Mn |
| Oct 2, 2021 | -5.00 Mn |